Diagnostics News and Research

RSS

Public Health Wales uses Luminex's xTAG GPP for outbreak investigations during Olympic events

Luminex Corporation announced today that Public Health Wales is using Luminex's CE marked xTAG Gastrointestinal Pathogen Panel (GPP) for outbreak investigation activities during Olympic and Paralympic training and events taking place in Wales. Results of a substantial diagnostic validation of the GPP test conducted by The Public Health Wales Microbiology laboratory team at the University Hospital of Wales, Cardiff, are anticipated to be published in a peer reviewed journal

From Luminex 6 Aug 2012

New sequencing approach can provide more effective method of BRCA1/2 mutational analysis

Individuals with mutations in BRCA1 and BRCA2 genes have a significantly higher risk of developing breast and ovarian cancers. Families at risk have been seeking genetic testing and counseling based on their mutation carrier status, but the standard method of direct sequencing is labor-intensive, costly, and it only targets a part of the BRCA1 and BRCA2 genes.

6 Aug 2012

SAGE Labs, Autism Speaks expand partnership to create first rat models for translational research

Autism Speaks, the world's leading autism science and advocacy organization, today announced its expanded collaboration with Sigma Advanced Genetic Engineering (SAGE) Labs, an initiative of Sigma- Life, to develop the first rat models with modified autism associated genes, intended to accelerate discovery and translational autism research.

3 Aug 2012

Weill Cornell Medical College receives NCATS grant to fund Clinical and Translational Science Center

Weill Cornell Medical College has received $49.6 million from the National Center for Advancing Translational Sciences (NCATS), of the National Institutes of Health (NIH), to fund its Clinical and Translational Science Center (CTSC).

3 Aug 2012

Narrative skills track cognition in children with language impairments

Children with specific language impairment show poor general narrative skills alongside deficits in verbal working memory and sustained auditory attention relative to children with typical development, research shows.

1 Aug 2012

Cervical cancer screening product from DySIS Medical recommended by NICE

DySIS Medical Ltd, the medical devices company in female health, announces that the National Institute for Health and Clinical Excellence (‘NICE’) has today published positive diagnostics guidance recommending its DySIS cervical cancer screening product to be considered in procurement plans.

1 Aug 2012

MDxHealth’s Irvine, California and CLIA laboratory receive CAP accreditation

MDxHealth SA, a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced that the company's Irvine, California, CLIA laboratory has received College of American Pathology (CAP) accreditation.

1 Aug 2012

Specific autoantibodies associated with blood vessel damage in the brain

The presence of specific autoantibodies of the immune system is associated with blood vessel damage in the brain. These findings were made by Marion Bimmler, a graduate engineer of medical laboratory diagnostics at the Max Delbr-ck Center for Molecular Medicine Berlin-Buch and Dr. Peter Karczewski of the biotech company E.R.D.E.-AAK-Diagnostik GmbH in studies on a rat model.

31 Jul 2012

GE Healthcare, Intermountain partner to help reduce radiation dose in CT procedures by 50%

Intermountain Healthcare today announced a joint effort with GE Healthcare to help further reduce radiation dose in Computed Tomography (CT) procedures at its facilities by up to 50 percent.

31 Jul 2012

NYGC purchases four Life Technologies' Ion Proton Sequencers

Life Technologies Corporation today announced that the New York Genome Center (NYGC) has purchased four Ion Proton Sequencers for its new Innovation Center.

31 Jul 2012

Life Technologies second quarter revenue increases 1% to $950 million

Life Technologies Corporation today announced results for its second quarter ended June 30, 2012.

31 Jul 2012

Registration now open for MedtechVision 2012 conference

MedtechWomen today announced that registration is now open for MedtechVision 2012: The Empowered Patient, the second annual conference designed by and for women on the forefront of medical innovation.

31 Jul 2012

Affymetrix second quarter total revenue increases to $66.4 million

Affymetrix, Inc., today reported its operating results for the second quarter of 2012. Total revenue for the quarter was $66.4 million, including approximately $1.4 million in revenue from eBioscience following the close of Affymetrix's acquisition of the company on June 25. This compares to total revenue of $64.7 million for the same period of 2011.

31 Jul 2012

Alseres enters agreement with Navidea to license Altropane imaging agent

Alseres Pharmaceuticals, Inc. today announced that it has entered into an agreement with Navidea Biopharmaceuticals, Inc. to license, [123I]-E-IACFT Injection (CFT), also called Altropane, an Iodine-123 radiolabeled imaging agent, being developed as an aid in the diagnosis of Parkinson's disease and movement disorders.

31 Jul 2012

Luminex second quarter consolidated revenue increases 1% to $48.3 million

Luminex Corporation today announced financial results for the second quarter ended June 30, 2012.

From Luminex 31 Jul 2012

GenomeQuest's genomic decision support system achieves HIPAA compliance

GenomeQuest Inc., a global provider of large-scale genomic software applications, today announced that its GQ-Dx genomic decision support system for the production of clinical-grade diagnostic reports from next-generation sequencing (NGS) runs now meets Health Insurance Portability and Accountability Act (HIPAA) security and privacy standards.

30 Jul 2012

Positive results from Vermillion OVA500 multi-center study for ovarian cancer

Vermillion, Inc., a leading molecular diagnostics company, today announced positive results from a new prospective, multi-center clinical study of its ovarian cancer diagnostic OVA1.

30 Jul 2012

Advaxis reports continued positive patient survival pattern in ADXS-HPV Phase 2 cervical cancer trial

Advaxis, Inc.,, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, presented updated preliminary data from an ongoing randomized Phase 2 trial of ADXS-HPV being conducted in India in women with recurrent/refractory cervical cancer who have failed previous cytotoxic therapy.

30 Jul 2012

MCW, Transgenomic partner to offer next-generation genetic testing services

Transgenomic, Inc. and the Medical College of Wisconsin today announced a collaboration agreement under which Transgenomic will offer next-generation genetic testing services performed at the MCW Clinical Sequencing Program. These services will initially include Transgenomic's NuclearMitome Test for mitochondrial disorders.

30 Jul 2012

Navidea announces results from Lymphoseek Phase 3 trial on head and neck squamous cell carcinoma

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, noted today that individual site, investigator-initiated results of an ongoing Phase 3 clinical trial of 99m-Tc-Tilmanocept (Lymphoseek) were presented at the American Head and Neck Society's 8th International Conference on Head and Neck Cancer (ICHNC), held in Toronto, July 21-25, 2012.

27 Jul 2012